Mantovani A, Bonecchi R, Locati MTuning inflammation and immunity by chemokine sequestration: decoys and more. Nat Rev Immunol 6:907-918

Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy and Istituto di Patologia Generale, Università degli Studi di Milano, Via Luigi Mangiagalli 31, 20133 Milan.
Nature reviews. Immunology (Impact Factor: 33.84). 01/2007; 6(12):907-18. DOI: 10.1038/nri1964
Source: PubMed

ABSTRACT A set of chemokine receptors are structurally unable to elicit migration or conventional signalling responses after ligand engagement. These 'silent' (non-signalling) chemokine receptors regulate inflammatory and immune reactions in different ways, including by acting as decoys and scavengers. Chemokine decoy receptors recognize distinct and complementary sets of ligands and are strategically expressed in different cellular contexts. Importantly, viruses and parasites have evolved multiple strategies to elude chemokines, including the expression of decoy receptors. So, decoy receptors for chemokines represent a general strategy to tune, shape and temper innate and adaptive immunity.

1 Follower
  • Source
    • "The most clinically relevant human data on CXCL8 refer to the correlation between high serum levels of the chemokine and poor prognoses, [42] [43] suggesting that patients expressing high levels of inflammatory cytokines or affected by inflammatory types of cancers are at a high risk of having aggressive cancers. Cancers associated with inflammation generally display the characteristics of aggressiveness [15] [44]. Since CXCL8 is not the only chemokine expressed under such circumstances, determination of its specific role is difficult. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although the functions of chemokines in the regulation of immune processes have been studied in some detail, the role of these biomolecules in cancer is not fully understood. Chemokines mediate migration of immune cells and other functions related to immunity. They are also involved in oncogenesis and in tumor progression, invasion, and metastasis through mechanisms similar to their roles in immune functions. Various chemokines also promote cell proliferation and resistance to apoptosis of stressed cells. Consequently, chemokines and their receptors present potential therapeutic targets for anticancer drugs. The chemokine CXCL8, also known as interleukin-8 (IL8), is a proinflammatory molecule that has functions within the tumor microenvironment. Due to its potent angiogenic effects and the activity of the chemokine and its receptors in the promotion of invasion and metastasis, CXCL8 and its receptors are now considered as attractive targets for cancer therapy. This review relates the current understanding of the regulation, signaling, and functions of CXCL8 that contribute to tumor growth and metastasis, and of its role in drug response.
    10/2013; 2013:859154. DOI:10.1155/2013/859154
  • Source
    • "Human islets express mRNAs encoding the non-signalling receptors CCRL1, CCRL2, CCBP2 and FY (DARC), all of which bind a large number of cytokines (Mantovani et al., 2006). It is possible that these receptors may influence islet function by either accumulating or removing ligands of other GPCRs from the microenvironment surrounding the islet cells and thereby influence signalling from other receptors. "
    [Show abstract] [Hide abstract]
    ABSTRACT: G-protein coupled receptors (GPCRs) regulate hormone secretion from islets of Langerhans, and recently developed therapies for type-2 diabetes target islet GLP-1 receptors. However, the total number of GPCRs expressed by human islets, as well as their function and interactions with drugs, is poorly understood. In this review we have constructed an atlas of all GPCRs expressed by human islets: the 'islet GPCRome'. We have used this atlas to describe how islet GPCRs interact with their endogenous ligands, regulate islet hormone secretion, and interact with drugs known to target GPCRs, with a focus on drug/receptor interactions that may affect insulin secretion. The islet GPCRome consists of 293 GPCRs, a majority of which have unknown effects on insulin, glucagon and somatostatin secretion. The islet GPCRs are activated by 271 different endogenous ligands, at least 131 of which are present in islet cells. A large signalling redundancy was also found, with 119 ligands activating more than one islet receptor. Islet GPCRs are also the targets of a large number of clinically used drugs, and based on their coupling characteristics and effects on receptor signalling we identified 107 drugs predicted to stimulate and 184 drugs predicted to inhibit insulin secretion. The islet GPCRome highlights knowledge gaps in the current understanding of islet GPCR function, and identifies GPCR/ligand/drug interactions that might affect insulin secretion, which are important for understanding the metabolic side effects of drugs. This approach may aid in the design of new safer therapeutic agents with fewer detrimental effects on islet hormone secretion.
    Pharmacology [?] Therapeutics 05/2013; 139(3). DOI:10.1016/j.pharmthera.2013.05.004 · 7.75 Impact Factor
  • Source
    • "to G-proteins. Receptors lacking the DRY motif sequester chemokines without launching a signalling cascade and are hence termed decoy receptors (Mantovani et al, 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Resolution of inflammation is a coordinated and active process aimed at restoration of tissue integrity and function. This review integrates the key molecular and cellular mechanisms of resolution. We describe how abrogation of chemokine signalling blocks continued neutrophil tissue infiltration and how apoptotic neutrophils attract monocytes and macrophages to induce their clearance. Uptake of apoptotic neutrophils by macrophages reprograms macrophages towards a resolving phenotype, a key event to restore tissue homeostasis. Finally, we highlight the therapeutic potential that derives from understanding the mechanisms of resolution.
    EMBO Molecular Medicine 05/2013; 5(5). DOI:10.1002/emmm.201202382 · 8.25 Impact Factor
Show more